Unleash Your Potential: Johnson & Johnson's 'Dual Control' Empowers IBD Patients in Asia Pacific

LB Pharma Targets $300 Million Valuation as It Gears Up for Landmark US IPO to Advance Autoimmune Therapies

Revolutionizing Drug Delivery: Mucus-Mimicking Spheres Break Through Biological Barriers

A Silent Epidemic: Bowel Diseases Surging in Young Children

Groundbreaking Study Dispels Fears: Antibiotics Unlikely to Trigger Most Autoimmune Diseases

Navigating the Labyrinth of Inflammatory Bowel Disease: A Deep Dive